References
- Benavente-Garcia O, Castillo J. (2008). Update on uses and properties of citrus flavonoids: New findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem 56:6185–205
- Borst P, Evers R, Kool M, Wijnholds J. (1999). The multidrug resistance protein family. Biochim Biophys Acta 1461:347–57
- Braillon A, Brody MJ. (1988). A simple method for chronic cannulation of the portal vein in intact unrestrained rats. Am J Physiol Gastrointest Liver Physiol 255:G191–3
- Gaitan E, Cooksey RC, Legan J, Lindsay RH. (1995). Antithyroid effects in vivo and in vitro of vitexin: A C-glucosylflavone in millet. J Clin Endocrino Metab 80:1144–7
- Hollman PCH, Hertog MGL, Katan MB. (1985). Role of dietary flavonoids in protection against cancer and coronary heart disease. Food Chem Toxicol 23:785–9
- Lee VHL, Sporty JL, Fandy TE. (2001). Pharmacogenomics of drug transporters: The next drug delivery challenge. Adv Drug Deliv Rev 50:S33–40
- Middleton E, Kandaswami C, Theoharides TC. (2000). The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673–751
- Peng XF, Zheng ZP, Cheng KW, et al. (2008). Inhibitory effect of mung bean extract and its constituents vitexin and isovitexin on the formation of advanced glycation endproducts. Food Chem 106:475–81
- Prabhakar MC, Bano H, Kumar I, et al. (2007). Pharmacological investigations on vitexin. Planta Med 43:396–403
- Saitoh H, Aungst BJ. (1995). Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm Res 12:1304–10
- Thummel KE, Kunze KL, Shen DD. (1997). Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 27:99–127
- Tong CL, Liu XD. (2006). Determination of vitexin in dog plasma by HPLC and study of its pharmacokinetics. Chin Pharmacol Bull 22:1149–50
- Tong CL, Liu XD. (2007). Pharmacokinetics of vitexin in rats. J China Pharm Univ 38:65–8
- US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Veterinary Medicine (CVM). (2001). Guidance for Industry: Bioanalytical Method Validation [Online]. Available at: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM070107.pdf [last accessed May 2001]
- Wandel C, Kim RB, Kajiji S, et al. (1999). P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies. Cancer Res 59:3944–8
- Wang SY, Chai JY, Zhang WJ, et al. (2010). HPLC determination of five polyphenols in rat plasma after intravenous administrating hawthorn leaves extract and its application to pharmacokinetic study. Yakugaku Zassh 130:1603–13
- Wang YJ, Han CH, Leng AJ, et al. (2012a). Pharmacokinetics of vitexin in rats after intravenous and oral administration. Afr J Pharm Pharmacol 6:2368–73
- Wang YJ, Qu GL, Zhang WJ, et al. (2012b). Pharmacokinetics, tissue distribution and excretion of vitexin in mice. Lat. Am J Pharm 31:844–51
- Zu YG, Zhang Q, Zhao XH, et al. (2012). Preparation and characterization of vitexin powder micronized by a supercritical antisolvent (SAS) process. Powder Technol 228:47–55